Endologix Stock Price, News & Analysis (NASDAQ:ELGX) Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.07▼$0.0850-Day Range$0.02▼$0.2252-Week Range$0.22▼$7.10Volume85,372 shsAverage Volume1.28 million shsMarket Capitalization$1.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/A About Endologix Stock (NASDAQ:ELGX)Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.Read More ELGX Stock News HeadlinesOctober 20, 2022 | businesswire.comEndovascular Aneurysm Repair Global Market Report 2022: Advantages Over Open Heart Surgery Driving Adoption & Growth - ResearchAndMarkets.com - Business WireOctober 19, 2022 | finance.yahoo.comVascular Grafts Market to record USD 1.55 Bn incremental growth; Market structure to be fragmented -- Technavio - Yahoo FinanceDecember 10, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 14, 2022 | finance.yahoo.comEndovascular Aneurysm Repair Global Market Report 2022: Next Generation Technologies Are Here, Shaping Future Growth Opportunities - Yahoo FinanceOctober 10, 2022 | businesswire.comEndologix Submits Premarket Approval (PMA) Application to FDA for the DETOURTM System. - businesswire.comSeptember 19, 2022 | prnewswire.comAortic Stent Grafts Market to record USD 781.72 Mn growth -- Driven by rising incidence of aortic aneurysms - PR NewswireSeptember 19, 2022 | globenewswire.comPeripheral Vascular Devices Market Size Worth US$ 16.46 Billion by 2030 at 6.3% CAGR, COVID-19 Impact and Global Analysis by Growth Plus Reports - GlobeNewswireAugust 18, 2022 | globenewswire.comEndovascular Aneurysm Repair Emerging as Frontrunner with Over Half Revenue Share of Vascular Grafts, Finds Fact.MR - GlobeNewswireDecember 10, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comAugust 8, 2022 | finance.yahoo.comGlobal Endovascular Devices Market valued at $5.4 billion in 2021, is expected to witness a decent growth rate of 5% by 2026 – Providing Hope to Patients Suffering from Vascular Diseases - Yahoo FinanceAugust 8, 2022 | uk.finance.yahoo.comGlobal Endovascular Devices Market valued at $5.4 billion in 2021, is expected to witness a decent growth rate of 5% by 2026 – Providing Hope to Patients Suffering from Vascular Diseases - Yahoo Finance UKAugust 4, 2022 | businesswire.comEndologix Receives CE Mark Certification under EU-MDR for AFX®2 Endovascular AAA System - Business WireJune 29, 2022 | finance.yahoo.comThe Global Vascular Stents Market to Surge at a CAGR of 7.90% by 2027 | DelveInsight - Yahoo FinanceJune 29, 2022 | finance.yahoo.comGlobal Endovascular Aneurysm Repair Market Size, Share & Industry Trends Analysis Report By Indication, By Product, By Site, By Anatomy, By Regional Outlook and Forecast, 2022 - 2028 - Yahoo FinanceJune 23, 2022 | finance.yahoo.comVascular Stent Market Research Report by Type, Material, Mode of Delivery, Product, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 - Yahoo FinanceMay 26, 2022 | finance.yahoo.comVascular Grafts Global Market Report 2022 - Yahoo FinanceMay 2, 2022 | finance.yahoo.comThe Abdominal Aortic Aneurysm Market to Boost at a CAGR of 3% During the Study Period (2019-32), Assesses DelveInsight - Yahoo FinanceApril 6, 2022 | finance.yahoo.comAllego® Expands Its Customer Base in the Age of Virtual Selling - Yahoo FinanceApril 5, 2022 | prnewswire.comAllego® Expands Its Customer Base in the Age of Virtual Selling - PR NewswireFebruary 9, 2022 | businesswire.comThe Worldwide Medical Device Industry is Expected to Reach $625.3 Billion by 2027 - ResearchAndMarkets.com - Business WireJanuary 12, 2022 | yahoo.comDr. Stephen J. Hoenig Completes First-of-its-Kind Procedure at The Vascular Care Group, Leominster - Yahoo FinanceJanuary 11, 2022 | finance.yahoo.comLESLIE NORWALK APPOINTED TO CENTENE BOARD OF DIRECTORS - Yahoo FinanceDecember 27, 2021 | bizjournals.comStartups to Watch: The 22 North Texas tech companies to have your eye on in 2022 - Philadelphia Business JournalDecember 8, 2021 | finance.yahoo.comWith Market Size Valued at $4.4 Billion by 2026, it`s a Healthy Outlook for the Global Vascular Grafts Market - Yahoo FinanceNovember 23, 2021 | prnewswire.comCoronary Stents Market is Expected to Grow at a CAGR of 7.50% and is Anticipated to Reach USD 10.97 Billion by 2026, Estimates DelveInsight - PRNewswireNovember 23, 2021 | businesswire.comEndologix Announces Completion of Enrollment in the TORUS 2 Study for PAD in SFA - Business WireNovember 10, 2021 | businesswire.comEndologix Names Dr. Matthew Thompson President and CEO - Business WireSee More Headlines Receive ELGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endologix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/11/2020Today12/10/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & Medical Instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:ELGX CUSIP29266S10 CIK1013606 Webwww.endologix.com Phone949-595-7200FaxN/AEmployees528Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,760,000.00 Net Margins-44.65% Pretax MarginN/A Return on Equity-63.96% Return on Assets-13.26% Debt Debt-to-Equity Ratio0.29 Current Ratio0.39 Quick Ratio0.28 Sales & Book Value Annual Sales$143.37 million Price / Sales0.01 Cash FlowN/A Price / Cash FlowN/A Book Value$3.56 per share Price / Book0.02Miscellaneous Outstanding Shares19,172,000Free FloatN/AMarket Cap$1.41 million OptionableOptionable Beta0.73 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. John Onopchenko (Age 60)CEO & Director Mr. Vaseem Mahboob (Age 50)Chief Financial Officer Dr. Michael V. Chobotov (Age 58)Chief Technology Officer Mr. Jeffrey S. BrownChief Operations OfficerMr. Jeremy B. Hayden (Age 49)Gen. Counsel Key CompetitorsAssureNASDAQ:IONMMotus GINASDAQ:MOTSDynatronicsNASDAQ:DYNTIntelligent Bio SolutionsNASDAQ:INBSInVivo TherapeuticsNASDAQ:NVIVView All Competitors ELGX Stock Analysis - Frequently Asked Questions How were Endologix's earnings last quarter? Endologix, Inc. (NASDAQ:ELGX) announced its earnings results on Monday, May, 11th. The medical instruments supplier reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.13. The medical instruments supplier had revenue of $28.51 million for the quarter, compared to analyst estimates of $28.50 million. Endologix had a negative trailing twelve-month return on equity of 63.96% and a negative net margin of 44.65%. When did Endologix's stock split? Endologix shares reverse split on Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 5th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Endologix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Endologix investors own include CA (CA), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM), Belden (BDC) and Precision Drilling (PD). This page (NASDAQ:ELGX) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endologix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.